Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases

Boehringer has licensed a small molecule program from Kyowa Kirin focused on developing potential treatments for autoimmune diseases. ......

Read Full Article →